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ABSTRACT
Anti-Müllerian hormone (AMH) is a glycoprotein produced by the granulosa cells of preantral and small antral follicles. AMH 
concentrations reflect ovarian physiology with high precision, thus serving as a more sensitive marker of the ovarian re-
serve than chronological age. This hormone plays a role in the pathogenesis of menstrual disorders and fertility in both 
obesity and polycystic ovary syndrome. The evaluation of AMH may also be useful in diagnosing or monitoring therapy 
of granulosa cell ovarian tumors.
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INTRODUCTION
Anti-Müllerian hormone (AMH), discovered in the 1950s 
by Alfred Jost and colleagues, is an important factor in-
volved in differentiation of the internal sex organs of the 
embryo [1]. Expression of the AMH gene, also known as MIS 
(Müllerian Inhibitor Substance), results in the loss of Müller 
ducts during sexual differentiation to the male gender [2]. 
In women, AMH is produced by granulosa cells in primordial 
preantral and small antral follicles and participates in follicu-
logenesis regulation. This occurs by inhibiting the germinal 
vesicle recruitment process through reduction of FSH’s ef-
fect on follicular growth of preantral and antral follicles.
The recent creation of commercially available diagnostic 
tests for measuring serum AMH concentration has allowed 
for wide-scale research studies focused on utilzing AMH 
as a clinical marker of the ovarian reserve. Additionally, 
it can also be used as a predictive factor with regards to 
ovarian stimulation with gonadotropins during ovulation 
stimulation. 
The evaluation of AMH in women participating in the 
program “Treatment of infertility by in vitro fertilization”, 
provided by the Ministry of Health, has become one of 
the selection criteria for assisted reproduction procedures.
This work summarizes the current knowledge about the 
role and use of AMH in gynecological practices.
ANTI-MÜLLERIAN HORMONE STRUCTURE
The anti-Müllerian hormone is a glycoprotein with a mo-
lecular weight of 140 kDa, belonging to the TGF-β growth 
factor superfamily. The human AMH gene is located on the 
short arm of chromosome 19 and is comprised of 275 base 
pairs, which are divided into five exons. Its gene product is 
a 560 amino acid precursor, proAMH. 24 amino acids consist-
ing fragment is removed from proAMH than the molecule is 
glycosylated. In the next step two identical proAMH subunits 
with a molecular weight of 70 kDa linked to each other by 
sulfide bridges. ProAMH proteolysis leads to the formation 
of the N-terminal fragment called the “pro-region” (115 kDa 
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AMHN), and a C-terminal domain, i.e. “mature region” (25 kDa 
AMHC). The C-terminal fragment is responsible for the bio-
logical activity of the protein and receptor binding, but in 
order to be active, it requires the N-terminal fragment unlike 
other proteins in the TGF-b family [3].
AMH acts on two types of receptors: AMH-I and AMH-II, 
both present in mesenchymal cells. AMH does not have di-
rect affinity for AMH-I; however, it binds to the AMH-II. This 
allows for the connection of receptor I and the formation of 
a large complex consisting of the AMH protein dimer, and 
two particles of both AMH-RI and AMH-RII. This combina-
tion induces tyrosine phosphorylation of AMH-RI, leading 
to further reactions in which the Smad protein complex 
(proteins involved in the signal transduction into the cell 
following TGF-β activation) is transported to the nucleus 
where it regulates gene transcription (Figure 1) [4, 5].
AMH AND FOLLICULOGENESIS
In females, fetal expression of AMH is observed from 
the 36th week of pregnancy. In women, AMH is produced 
by granulosa cells in primordial preantral and small antral 
follicles. The production of AMH in the follicle starts from 
the moment of its recruitment and lasts to antral stage 
development. The highest level of hormone synthesis is 
observed in granulosa cells of preantral and small antral 
follicles (to 4 mm). In larger antral follicles (> 8 mm), AMH 
synthesis slowly decreases until it becomes undetectable [6].
AMH inhibits gene and protein lexpression of cy-
tochrome P450 in aromatase granular cells [7]. By reduc-
ing the effect of FSH on preantral and antral follicle growth, 
the anti-Müllerian hormone participates in the regulation 
of folliculogenesis, thereby inhibiting the recruitment of 
germinal vesicles.
Knowledge concerning the effect of AMH on folliculo-
genesis was discovered using mice lacking the AMH (type 
null). The ovaries of four-month-old null mice were twice 
as large as a wild type mouse, and they contained a lower 
number of germinal vesicles and a three-fold increase in 
small growing vesicles [5]. This was due to the increased 
recruitment of primordial follicles and their transformation 
to preantral and antral follicles.
Null mice with the larger number of follicles also showed 
lower levels of FSH, which allowed for the hypothesis that, 















Figure 1. The mechanism of AMH action via receptor Proteolysis of AMH pro leads to a conformational change in the C -terminal domain that 
allows binding AMRH II. AMH-RII induces binding type I receptor, which is phosphorylated by a kinase receptor type II. The activated AMH-RI in turn 
phosphorylates further Smads proteins. Phosphorylated Smads specific receptors translocate to the nucleus, where they regulate gene expression
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influence of FSH. In in vitro mouse studies, AMH addition to 
follicular culture inhibited FSH-dependent follicular growth, 
resulting in a smaller follicle diameter [8]. In vivo studies on 
null mice showed greater follicle growth occurred at low and 
at high exogenous FSH administration as compared to wild 
type animals. The inhibitory effect of AMH on FSH follicular 
sensitivity may occur during the follicle selection process [5].
Current theories suggest that AMH acts as a co-regulator 
of steroidogenesis in granulosa cells. As it has been shown, 
the AMH concentraiton correlates with estradiol levels in 
small antral follicle fluid. Studies have shown a relationship 
between an AMH gene polymorphism or the AMH receptor 
type II and the level of estradiol in the follicular phase, point-
ing to a role for AMH in FSH-dependent steroidogenesis in 
the human ovary [9].
AMH is detected in the serum, although its main role is 
auto and paracrine action on follicular development. Antral 
follicles appear to be a major source of AMH in the serum 
because of the larger number of granulosa cells. The pres-
ence of AMH in the blood stream has been the subject of 
many studies that are focused on the possibility of the use 
of hormone evaluation in the diagnosis of endocrine and 
oncological disorders.
AMH AS A MARKER OF FEMALE FERTILITY
During a woman’s life, serum AMH concentrations in 
serum are low after birth and during the prepubertal phase. 
At puberty, AMH concentration the in blood increases, peak-
ing at approximately 20–25 years of age. After this time, 
hormone concentrations decreases to undetectable levels 
following menopause [10].
AMH appears to be a good marker in the assessment of 
the ovarian reserve. In women, AMH levels decrease with 
age before signs of upcoming menopause manifest, such as 
an increase in FSH concentration or a decrease in the num-
ber of antral follicles. During menopause, AMH becomes 
undetectable, a phenomena associated with the depletion 
of the follicular reserve. Thus, the reduced concentration of 
serum AMH may indicate the physiological or pathological 
aging of the ovary [11]. 
During one menstrual cycle, hormone levels are not sig-
nificantly affected [12, 11], although Wunder et al. showed 
lower concentrations of AMH in the early luteal phase [13]. 
The described variation in the cycle is not significant enough 
to recommend AMH measurements on specific days of the 
menstrual cycle.
Various factors have been reported to influence differ-
ences in AMH concentrations: ethnicity, smoking, vitamin D 
levels, and obesity. It was found that African-American and 
Spanish women have lower values of AMH than Cauca-
sian women. Also, women who smoke present a lower level 
of anti-Müllerian hormone than non-smokers [14]. Sowers et 
al. has shown that, in smokers, AMH concentrations decrease 
faster, and these women reach the age of menopause earlier 
than non-smokers [15]. A positive correlation between se-
rum 25-hydroxy vitamin D and serum AMH has been shown, 
which may be related to the presence of a binding complex 
for vitamin D in the promoter of the AMH gene [13]. It has 
been noted that the concentration of AMH and inhibin B 
is lower in women with a high BMI but without Polycystic 
Ovary Syndrome (PCOS) [16]. In the study of obese women 
compared to those of normal weight, a decreased level of 
AMH was observed; however, there were no differences 
between the amount of antral follicles in the USG image [17]. 
Nevertheless, the effectiveness of in vitro fertilization (IVF) 
programs in obese women is also smaller. The correlation 
mechanisms between obesity and ovarian function with 
respect to AMH production are not fully understood. One 
mechanism may include a lipotoxicity effect on granular 
cells. In a mouse study in which animals were treated with 
a high-fat diet, a higher percent of anovulation cycles was 
observed. Additionally, decreased fertility, lipid accumula-
tion, endoplasmic reticulum stress, mitochondrial dysfunc-
tion, and apoptosis of granular cells and the crown were 
noted [18]. 
It has been observed that in women with PCOS syn-
drome (Polycystic Ovary Syndrome), the level of AMH is 
2–3 times higher than in healthy women with normal ovula-
tion. A growing number of studies suggest that the diagno-
sis of PCOS, which is now determined using an ultrasound 
evaluation of the ovaries, anovulatory cycles, and hyperan-
drogenemia, should be replaced by the measurement of 
AMH. Carrying out a meta-analysis of anti-Müllerian hor-
mone concentrations in women with PCOS (AMH cut-off 
of 4.7 ng/mL), the obtained sensitivity and specificity were 
82.8% and 79.4%, respectively [12]. Histological examina-
tion of the ovaries of women with PCOS showed a normal 
number of primordial follicles, and a two-fold increase in 
the number of growing follicles. The elevated level of AMH 
is connected with a larger number of preantral and small 
antral follicles, which are the major source of the hormone. 
The high level of AMH is responsible for follicle growth in-
hibition during the selection process of a dominant follicle 
through the negative correlation of AMH and FSH, thereby 
leading to oligoovulation. Anti-Müllerian hormone inhibits 
aromatase synthesis, which is activated by the action of 
FSH on granular cells. Higher concentrations of AMH are 
observed in patients with insulin resistance as compared to 
patients with normal insulin sensitivity [7]. Similarly, women 
with anovulation have a higher level of AMH than those who 
are oligoovulatory , which may point to a role of AMH in 
PCOS pathogenesis in patients with anovulatory cycles. High 
concentrations of AMH have also been demonstrated in 
adolescent girls (12–18 years) with PCOS [19], as well as in 
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4–7-year-old daughters of women suffering from this dis-
ease. The AMH concentration in women with PCOS declines 
with age, but it clearly occurs after the 40th decade of life.
THE USE OF AMH IN ASSISTED 
REPRODUCTION TECHNIQUES
The level of AMH slowly drops after gonadotropin 
treatment during controlled ovarian stimulation [20]. This 
decrease could be an effect of a direct or indirect negative 
influence of FSH on AMH ovarian secretion. The exogenous 
FSH treatment elevates estradiol, which could be the source 
of AMH decrease as estradiol negatively influences the regu-
lation of AMH and AMHII mRNA in the ovary [21].
Studies have reported a positive correlation between 
serum AMH levels and the number of obtained eggs [20]. It 
appears that the pretreatment level of AMH is a better prog-
nostic marker than patient age, the level of FSH on the 3rd day 
of the cycle, and the levels of estradiol or inhibin B. A number 
of antral follicles (AFC-antral follicle count) in the USG image 
were positively correlated with AMH concentration. Low lev-
els of anti-Müllerian hormone and AFC are weak prognostic 
markers for stimulation in in vitro fertilization (IVF), and they 
are considered to be equivalent parameters for prediction 
of treatment success. The risk of IVF cycle cancellation could 
be 13 times higher in patients with undetectable AMH levels 
than in those with an AMH level higher than 2.0 ng/mL [22]. 
Decreased AMH concentrations do not exclude the pos-
sibility of getting pregnant, although the success rate is 
much lower. In a study by Kedema et al. [23], conducted in 
769 IVF/ICSI cycles, the rate of achieved pregnancies was 
the same and equal to 4.4% in two studied groups. In one 
group of patients the level of AMH was low (0,2–1,0 ng/mL) in 
second group extremely low (< 0.2 ng/mL). In women older 
than 42 years of age, with AMH concentrations < 0.2 ng/mL, 
pregnancy was not achieved. However, analysis presented 
by Łukaszuk et al. [24] examined 101 women with AMH 
levels < 0.4 ng/mL during 188 in vitro cycles and achieved 
14 live births, making the IVF procedure 7.45% effective. 
Thus, low concentrations of AMH require different stimula-
tion protocols, in particular, short and ultrashort protocols 
with high initial dosages of gonadotropins [22]. 
The evaluation of anti-Müllerian hormone is an impor-
tant predictor factor of ovarian hyperstimulation syndrome 
(OHSS) risk. AMH is a better prediction marker for an exces-
sive ovarian response due to its stimulation as opposed 
to gonadotropin level, age, or BMI. It is also more precise 
than follicle number in the USG image or the estradiol level 
after HCG administration. A value 3.5 ng/mL is considered 
the cut-off point, indicating a high risk of OHSS. During the 
cycles of in vitro fertilization, it is recommended to use low 
initial doses of gonadotropins and protocols with a GnRH 
antagonist [20].
In a prospective study, Nelson et al. showed a higher 
rate of live births is associated with higher concentrations 
of AMH. However, the authors suggest that such a good cor-
relation may be related to a greater number of oocytes [25]. 
Other randomized studies conducted by Brodin et al. [26] on 
842 women confirmed a strong positive correlation between 
the serum AMH levels and the amount of received oocytes, 
the rate of achieved pregnancies, as well as a cumulative 
indicator of live births.
It seems that AMH is a good marker for quantitative, 
rather than qualitative, techniques of assisted reproduction. 
The individual selection of the type of stimulation protocol 
and doses of gonadotropins in IVF programs, based on the 
concentration of AMH, allows for a safer and more effective 
use of in vitro fertilization.
AMH AS A CANCER MARKER
The expression of AMH by granulosa cells of ovar-
ian small antral and primordial follicles attempted to use 
AMH as a marker of cancer derived from granular cells (GTCs, 
granulosa cell tumors). These tumors comprise about 3% to 
5% of all ovarian tumors. It was noted that AMH concentra-
tion was elevated in 76–93% of women with tumor cells 
derived from granular cells [27]. Furthermore, higher con-
centrations of AMH were observed up to 16 months before 
tumor relapse. Therefore, the determination of the hormone 
value is a useful marker in detecting recurrences of GTCs, 
in particular by using new generation ultrasensitive assays.
Recent studies indicate that a large number of primary 
epithelial ovarian tumors originate from the scrap of the 
fallopian tubes or the components of the secondary Müller 
system. Based on the fact that AMH is responsible for the 
regression of the Müllerian ducts, there has been an attempt 
to use this hormone in the treatment of epithelial ovarian can-
cers. Growth inhibition in epithelial tumor cell lines after 
incubation with the AMH was achieved in in vitro studies [28].
Chemotherapy is particularly toxic for the ovaries by pro-
moting follicle injury. It has been shown that, after chemo-
therapy, AMH concentration is significantly lower than in 
healthy women at a similar age, which confirms the idea 
that the hormone is a sensitive indicator of ovarian reserve. 
Depending on the drugs and doses used in therapy, AMH 
levels after treatment may vary. Hormone levels were shown 
to be significantly lower or almost undetectable after the 
therapy with alkylating agents in comparison to other types 
of chemotherapy. The elevation of AMH after chemotherapy 
depends on the type of the treatment protocol [29].
AMH was identified as a marker used to classify pa-
tients for fertility preservation procedures before antican-
cer therapy. Therefore, it is important to direct women to 
infertility treatment facilities as soon as possible to select 
the appropriate treatment options such as cryopreservation 
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of the obtained embryos, oocytes, or freezing ovarian tissue 
for the afterward transplant.
AMH MEASUREMENT
Initial reports determining anti-Müllerian hormone con-
centrations first emerged in the 90’s of XX century. The first 
generation, commercially available tests were produced by 
Diagnostics Systems Ltd. (DSL) and Immunotech Ltd. (IOT). 
Each test contained different types of antibodies and stand-
ards, a reason for differences in reported AMH levels [30]. 
Subsequent analysis showed similarity in AMH levels, po-
tentially a result of kit improvement. The consolidation of 
the two companies by Beckman Coulter resulted in the 
introduction of one test, AMH Gen II Assay, which contained 
antibodies from the DSL kit and standards from IOT kit. The 
AMH results obtained with using the second-generation test 
were about 22–40% higher than the first generation test 
results; however, they corresponded with each other [31]. 
Further studies discredit the serum sample stability during 
storage time, dilution, and even AMH measurement [32]. 
Rustamov et al. noted that the level of AMH obtained with 
the AMH Gen II kit was approximately 20% lower than the 
results obtained by the DSL kit. The decrease in quality of the 
second-generation tests (also those produced since the year 
2012, AMH Gen II kit with IVD certificate) was demonstrated 
during an analysis conducted in 8,323 samples. Levels of 
AMH obtained by the second-generation test, Gen II IVD, 
were 40% lower than the previous generation of Gen II kit 
and 70% lower than the IOT kit [33]. In response to reports 
regarding test accuracy, Beckman Coulter introduced a new 
protocol for AMH evaluation with the recommendation of 
serum pre-incubation with a suitable buffer (Conference 
ESHRE, London 2013) prior to measurement. The dilution of 
the sample was to prevent errors resulting from the effect 
of complement protein binding. Additionally, to improve 
sample stability, it was reccommended to freeze the serum 
within two hours after its collection. 
The newest generation tests like Ultrasensitive (2012) 
and PicoAMH (2013), produced by AnsLabs, show a higher 
sensitivity and detection threshold than AMH Gen II IVD 
(0.023 vs. 0.001 vs. 0.08 ng/mL, respectively), and they could 
be more useful in detecting low levels of anti-Müllerian hor-
mone [34]. Published data has pointed out the necessity of 
a cautious interpretation of results obtained using the AMH 
Gen II kit. For that reason, it seems to be rather impossible 
to compare the results, cut-off points, or clinically impor-
tant values obtained with the test produced by different 
manufacturers.
The introduction of the first automatic AMH test in Sep-
tember 2014 by Elecsys (ECLIA method) Roche could be the 
next step in the creation of a test appropriate in clinical prac-
tice. The manufacturer assigned individual reference ranges 
for women at different ages and defined the cut-off value for 
AMH in patients with PCOS [35]. The determination of an in-
ternational AMH standard could be an important step toward 
the creation of a test completely useful in clinical practice. 
SUMMARY
Anti-Müllerian hormone reflects ovarian function with 
high precision. AMH is a more sensitive marker of ovarian re-
serve than chronological age, and, for this reason, it seems 
very helpful in reproductive planning for women using both 
natural and assisted reproductive technologies. It is also one 
of the elements of pathogenesis of menstrual disorders and 
fertility in obese women in cases with and without PCOS 
coexistence. The evaluation of AMH may be very useful in 
diagnosing or monitoring the treatment of ovarian cancer 
derived from granulosa cells.
REFERENCES
1. Josso N. Professor Alfred Jost: The Builder of Modern Sex Differentiation. 
Sex Dev. 2008, 2, 55-63.
2. Charon KM, Świtoński M. Genetyka zwierząt. Warszawa. PWN, 2004.
3. Pepinsky RB, Sinclair LK, Chow EP. Proteolytic processing of mulle-
rian inhibiting substance produces a transforming growth factor-β-like 
fragment. J Biol Chem. 1988, 263, 18961–18964.
4. Skałba P, Cygal A, Dąbkowska-Huć A. Wpływ hormonu anty-Mullerow-
skiego (AMH) na folikulogenezę. Ginekol Pol. 2008, 79, 137–140.
5. Durlinger A, Kramer P, Karels B, [et al.]. Control of primordial follicle 
recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinol. 
1999, 140, 5789–5796.
6. Jeppesen JV, Anderson RA, Kelsey TW, [et al.] Which follicles make 
the most anti-Mullerian hormone in humans? Evidence for an abrupt 
decline in AMH production at the time of follicle selection. Mol Hum 
Reprod. 2013, 19, 519–527
7. Grossman M, Nakaji S, Fallat M, [et al.]. Müllerian inhibiting substance 
inhibits cytochromeP450 aromataze activity in human granulosa lutein 
cell culture. Fertil Steril. 2008, 89, 1364–1370.
8. Durlinger A, Gruijters M, Kramer P, [et al.]. Anti-Müllerian hormone at-
tenuates the effect of FSH on follicle development in the mouse ovary. 
Endocrinol. 2001, 142, 4891–4899.
9. Kevenaar ME, Themmen AP, Laven JS, [et al.]. Anti-Müllerian hormone 
and anti-Müllerian hormone type II receptor polymorphisms are associ-
ated with follicular phase estradiol levels in normo-ovulatory women. 
Hum Reprod. 2007, 22, 1547–1554.
10. Lie Fong S, Visser JA, Welt CK, [et al.]. Serum anti-müllerian hormone 
levels in healthy females: a nomogram ranging from infancy to adult-
hood. J Clin Endocrinol Metab. 2012, 97, 4650–4655.
11. De Vet A, Loven J, de Jong F, [et al.]. Anti-Müllerian hormone serum 
levels: a putative marker for ovarian aging. Fertil Steril. 2002, 77, 357–362.
12. Iliodromiti S, Kelsey TW, Anderson RA, [et al.]. Can anti-Mullerian hor-
mone predict the diagnosis of polycystic ovary syndrome? A systematic 
review and meta-analysis of extracted data. J Clin Endocrinol Metab. 
2013, 98, 3332–3340.
13. Wunder DM, Bersinger NA, Yared M, [et al.]. Statistically significant 
changes of antimüllerian hormone and inhibin levels during the 
physiologic menstrual cycle in reproductive age women. Fertil Steril. 
2008, 89, 927–933.
14. Tal R, Seifer DB. Potential mechanisms for racial and ethnic differences in 
antimüllerian hormone and ovarian reserve. Int J Endocrinol. 2013: 818912.
15. Sowers MR, McConnell D, Yosef M, [et al.]. Relating smoking, obesity, 
insulin resistance and ovarian biomarker changes to the final menstrual 
period (FMP) Ann N Y Acad Sci. 2010, 1204, 95–103.
16. Freeman E, Gracia C, Sammel M, [et al.]. Association of anti-Müllerian hor-
mone levels with obesity in late reproductive age woman. Feril Steril. 
2007, 87, 101–106.
17. Su HI, Sammel M, Freeman E, [et al.]. Body size affects measures of 
ovarian reserve in late reproductive age women. Menopause. 2008, 
15, 857–861.
537
Marzena Rzeszowska et al., Anti-Müllerian hormone: a critical factor for female fertility and reproductive health
www. journals.viamedica.pl/ginekologia_polska
18. Wu LL-Y, Dunning KR, Yang X, [et al.]. Hight-fat diet causes lipotoxicity 
responses in cumulus- oocyte complexes and decreased fertilization 
rates. Endocrinol. 2010, 151, 5438–5445.
19. Siow Y, Kives S, Hertweck P, [et al.]. Serum Müllerian-inhibiting substance 
levels in adolescent girls with normal menstrual cycles or with polycystic 
ovary syndrome. Fertil Steril. 2005, 84, 938–944. 
20. La Marca A, Sunkara SK. Individualization of controlled ovarian stimula-
tion in IVF using ovarian reserve markers: from theory to practice. Hum 
Reprod Update. 2014 20, 124–140.
21. Baarends W, Uilenbroek J, Kramer P, [et al.]. Anti-Mullerian hormone 
type II receptor maeesenger ribonucleotic acid expression in rat ovaries 
during postnatal development, the estrous cycle, and gonadotropin-in-
duced follicle growth. Endocrinol. 1995, 136, 4951–4962.
22. Reichman DE, Goldschlag D, Rosenwaks Z. Value of antimüllerian hor-
mone as a prognostic indicator of in vitro fertilization outcome. Fertil 
Steril. 2014 101, 1012.
23. Kedem A, Haas J, Geva LL, [et al.]. Ongoing pregnancy rates in women 
with low and extremely low AMH levels. A multivariate analysis of 769 
cycles. PLoS One. 2013, 16, 8, e81629.
24. Łukaszuk K, Kunicki M, Liss J, [et al.]. Probability of live birth in women 
with extremely low anti-Müllerian hormone concentrations. Reprod 
Biomed Online. 2013, 28, 64–69.
25. Nelson SM, Yates RW, Lyall H, [et al.]. Anti-Müllerian hormone-based 
approach to controlled ovarian stimulation for assisted conception. 
Hum Reprod. 2009, 24, 867–875.
26. Brodin T, Hadziosmanovic N, Berglund L, [et al.]. Antimüllerian hormone 
levels are strongly associated with live-birth rates after assisted repro-
duction. J Clin Endocrinol Metab. 2013, 98, 1107–1114. 
27. Rey RA, Sabourin J, Venara M, [et al.]. Anti-Müllerian hormone is specific 
marker of sertoli- and granulose-cell origin in gonadal tumors. Hum 
Pathol. 2000, 31, 1202–1203.
28. Stephen A, Pearsoll L, Christian B, [et al.]. Highly purified Müllerian in-
hibiting substance inhibits human ovarian cancer in vivo. Clin Cancer 
Res. 2002, 8, 2640–2646.
29. Peigné M, Decanter C. Serum AMH level as a marker of acute and 
long-term effects of chemotherapy on the ovarian follicular content: 
a systematic review. Reprod Biol Endocrinol. 2014, 26, 26.
30. Bersinger NA, Wunder D, Birkhauser MH, [et al.]. Measurement of 
anti-müllerian hormone by Beckman Coulter ELISA and DSL ELISA in 
assisted reproduction: differences between serum and follicular fluid. 
Clin Chim Acta. 2007, 384, 174–175.
31. Wallace AM, Faye SA, Fleming R, [et al.]. A multicentre evaluation of the 
new Beckman Coulter anti-Mullerian hormone immunoassay (AMH Gen 
II). Ann Clin Biochem. 2011, 48, 370–373.
32. Rustamov O, Smith A, Roberts SA, [et al.]. Anti-Mullerian hormone: poor 
assay reproducibility in a large cohort of subjects suggests sample 
instability. Hum Reprod. 2012, 27, 3085–3091.
33. Łukaszuk K, Ludwikowska B, Liss J, [et al]. Decreasing quality of the 
new generations of anti-Müllerian hormone assays. Biomed Res Int. 
2014, 2014, 165352.
34. Su HI, Sammel MD, Homer MV, [et al.]. Comparability of antimüllerian hor-
mone levels among commercially available immunoassays. Fertil Steril. 
2014, 101, 1766–1772.
35. Gassner D, Jung R. First fully automated immunoassay for anti-Mülle-
rian hormone. Clin Chem Lab Med. 2014, 52, 1143–1152.
